Division of GlaxoSmithKline PLC
Latest From Tesaro Inc.
Chief scientific offficer Hal Barron talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
The latest drug development news and highlights from our US FDA Performance Tracker.
As it continues to build a presence in oncology, the company is starting a late-stage trial of GSK3359609 combined with Merck & Co's blockbuster Keytruda on the back of data presented at ESMO.
The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Lonnie Moulder, CEO
Timothy Pearson, EVP, CFO
Mary Lynne Hedley, PhD, Pres. & COO
Grant C Bogle, SVP, Chief Commercial Officer
William Aitchison, PhD, SVP, Technical ops
Allene Diaz, SVP, Global Commercial Development
Joseph Farmer, SVP, General Counsel & Corp Secretary
Martin Huber, MD, SVP, CMO
Jennifer Jackson, PhD, SVP, Global RA and QA
Orlando Oliveira, SVP, International
- Contact Info
Phone: (339) 970-0900
1000 Winter St.
Waltham, MA 02451
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.